Dyskinesias induced by focused ultrasound subthalamotomy in Parkinson's disease are associated with better patient impression of change.
Dyskinesias induced by focused ultrasound subthalamotomy in Parkinson's disease are associated with better patient impression of change.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Centro, ES · Author affiliation
HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain; Instituto de Investigación Sanitaria HM Hospitales , Spain; PhD Neurosciences Program, Universidad Autónoma de Madrid, Madrid, Spain.Location evidence
Madrid, ES · Author affiliation
HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain; Instituto de Investigación Sanitaria HM Hospitales , Spain; PhD Neurosciences Program, Universidad Autónoma de Madrid, Madrid, Spain.Location evidence
Universidad, ES · Author affiliation
HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain; Instituto de Investigación Sanitaria HM Hospitales , Spain; PhD Neurosciences Program, Universidad Autónoma de Madrid, Madrid, Spain.Location evidence
Móstoles, ES · Author affiliation
Rey Juan Carlos University Hospital, Móstoles, Madrid, Spain.Location evidence
Valencia, ES · Author affiliation
Vithas 9 de Octubre Hospital, Valencia, Spain.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
BACKGROUND: Unilateral magnetic resonance-guided focused ultrasound (MRgFUS) subthalamotomy is an effective treatment for asymmetric Parkinson's disease (PD) although it may induce dyskinesias in some patients. OBJECTIVES: We aim to assess how post-treatment dyskinesias impact patient-reported outcomes, parkinsonian improvement, and quality of life (QoL). METHODS: Thirty-four PD patients underwent MRgFUS subthalamotomy in a randomized controlled trial. They were retrospectively divided into those who developed dyskinesias (PD-Dysk) and those who did not (PD-NoDysk). Outcomes included Patient's Global Impression of Change (PGI-C), MDS-UPDRS III, levodopa equivalent daily dose (LEDD) reduction, and QoL change (PDQ-39) through 30 months. RESULTS: At four months, PD-dysk patients (n = 13) reported greater PGI-C improvement (P = 0.027) and greater LEDD reduction (P = 0.015). At 30 months, the PGI-C was numerically more favorable in PD-dysk patients, but the difference was not statistically significant (P = 0.061). Total motor improvement did not differ significantly between groups, with greater treated-side off-medication improvement in PD-dysk patients at 4 and 12 months. QoL changes did not differ significantly. CONCLUSION: Post-MRgFUS dyskinesias were associated with better perceived improvement at four months, with no statistically significant between-group differences detected in QoL or other outcomes.